Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
Fuller
L M
LM
Department of Clinical Radiotherapy, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Hagemeister
F B
FB
D000008:Abdominal Neoplasms / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005298:Fertility / Q000528:radiation effects; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D008479:Mediastinal Neoplasms / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone